Synonyms: faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo®
faricimab is an approved drug (FDA (2022))
Compound class:
Antibody
Comment: Faricimab is a bispecific monoclonal antibody that simultaneously binds to angiopoietin 2 (Ang2) and vascular endothelial growth factor A (VEGF-A) [3-4]. It is an angiogenesis inhibitor. The FcRn and FcγR binding sites of faricimab have been modified to disable its Fc‐mediated effector functions. Faricimab does not bind to Ang1 [4].
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2022)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10563 | faricimab |
Synonyms ![]() |
faricimab-svoa | RG-7716 | RG7716 | RO-6867461 | RO6867461 | Vabysmo® |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 793 |
Other databases | |
GtoPdb PubChem SID | 440816789 |
Search PubMed clinical trials | faricimab |
Search PubMed titles | faricimab |
Search PubMed titles/abstracts | faricimab |